Macitentan 10 MG Oral Tablet [Opsumit] — RxCUI 1442143
RxNorm drug concept · Semantic branded drug
RxCUI 1442143
Semantic branded drug · SBD
● Current RxNorm concept 1 FDA product
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1442143
Official nameMacitentan 10 MG Oral Tablet [Opsumit]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asOpsumit 10 MG Oral Tablet
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)17,860 prescriptions · 47 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Macitentan: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Macitentan works by blocking a protein called endothelin-1 that causes the blood vessels in your lungs to narrow and stiffen — that's what drives pulmonary arterial hypertension. B...
- What exactly does macitentan do, and why do I need to take it every day?
- Good news — you can take macitentan with or without food. Studies showed that even a high-fat meal doesn't meaningfully change how much of the drug gets into your system. The most...
- Can I take this pill with food, or do I need to take it on an empty stomach?
🕸️ Concept Web — How Macitentan 10 MG Oral Tablet [Opsumit] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Macitentan 10 MG Oral Tablet [Opsumit]
RxCUI 1442143 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Macitentan
1442132IN
-
Macitentan
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Opsumit
1442138BN
-
Opsumit
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Macitentan Oral Tablet
1442136SCDF -
Macitentan Oral Product
1442134SCDG -
Macitentan Pill
1442135SCDG -
Macitentan Oral Tablet [Opsumit]
1442140SBDF -
Opsumit Oral Product
1442141SBDG -
Opsumit Pill
1442142SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Macitentan Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Macitentan 10 MG Oral Tablet
1442137SCD -
Macitentan 10 MG
1442133SCDC -
Macitentan 10 MG [Opsumit]
1442139SBDC
-
Macitentan 10 MG Oral Tablet
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Macitentan 10 MG Oral Tablet
SCD · 1442137 -
Macitentan 10 MG
SCDC · 1442133 -
Macitentan Oral Tablet
SCDF · 1442136 -
Macitentan Oral Product
SCDG · 1442134 -
Macitentan Pill
SCDG · 1442135
Brand-Name Concepts
-
Macitentan 10 MG [Opsumit]
SBDC · 1442139 -
Macitentan Oral Tablet [Opsumit]
SBDF · 1442140 -
Opsumit Oral Product
SBDG · 1442141 -
Opsumit Pill
SBDG · 1442142 -
Opsumit
BN · 1442138
📦 FDA Products & Package NDCs
1 product · 2 package NDCs
2 package NDCs map to RxCUI 1442143 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 66215-0501-15 | 1 BLISTER PACK in 1 CARTON (66215-501-15) / 15 TABLET, FILM... | OPSUMIT | Actelion Pharmaceuticals US, Inc. | 2013-11-04 |
| 66215-0501-30 | 1 BOTTLE in 1 CARTON (66215-501-30) / 30 TABLET, FILM COATE... | OPSUMIT | Actelion Pharmaceuticals US, Inc. | 2013-11-04 |
Observed labelers:
Actelion Pharmaceuticals US, Inc. (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.